Comparison of ETP and peak height measurements (TF0.5 pM) between controls and FXI-deficient patients divided into nonbleeder and bleeder groups
TG parameter and sample conditions . | Controls (n = 50) . | Nonbleeders (n = 50) . | Bleeders (n = 24) . | P nonbleeder vs control . | P bleeder vs control . | P bleeder vs nonbleeder . |
---|---|---|---|---|---|---|
ETP (nM*mins) | ||||||
PRP CTI | 1020 ± 234 | 957 ± 262 | 522 ± 166 | ns | **** | **** |
PRP no CTI | 1433 ± 215 | 1395 ± 294 | 1143 ± 420 | ns | ** | ** |
PPP CTI | 302 ± 103 | 275 ± 125 | 209 ± 138 | ns | *** | * |
PPP no CTI | 1407 ± 223 | 1165 ± 414 | 706 ± 416 | ** | **** | **** |
Peak height (nM) | ||||||
PRP CTI | 58.6 ± 15.3 | 44.2 ± 16 | 21.8 ± 8.1 | *** | **** | **** |
PRP No CTI | 111 ± 22.2 | 89.9 ± 27.5 | 67.7 ± 32.4 | *** | **** | ** |
PPP CTI | 18.2 ± 7.9 | 15.2 ± 9.6 | 9.3 ± 7.1 | ns | **** | ** |
PPP No CTI | 335 ± 60.7 | 217 ± 104 | 105 ± 84.1 | **** | **** | ** |
TG parameter and sample conditions . | Controls (n = 50) . | Nonbleeders (n = 50) . | Bleeders (n = 24) . | P nonbleeder vs control . | P bleeder vs control . | P bleeder vs nonbleeder . |
---|---|---|---|---|---|---|
ETP (nM*mins) | ||||||
PRP CTI | 1020 ± 234 | 957 ± 262 | 522 ± 166 | ns | **** | **** |
PRP no CTI | 1433 ± 215 | 1395 ± 294 | 1143 ± 420 | ns | ** | ** |
PPP CTI | 302 ± 103 | 275 ± 125 | 209 ± 138 | ns | *** | * |
PPP no CTI | 1407 ± 223 | 1165 ± 414 | 706 ± 416 | ** | **** | **** |
Peak height (nM) | ||||||
PRP CTI | 58.6 ± 15.3 | 44.2 ± 16 | 21.8 ± 8.1 | *** | **** | **** |
PRP No CTI | 111 ± 22.2 | 89.9 ± 27.5 | 67.7 ± 32.4 | *** | **** | ** |
PPP CTI | 18.2 ± 7.9 | 15.2 ± 9.6 | 9.3 ± 7.1 | ns | **** | ** |
PPP No CTI | 335 ± 60.7 | 217 ± 104 | 105 ± 84.1 | **** | **** | ** |
Comparison of results (mean ± standard deviation) between groups was performed using ANOVA test with the Bonferroni multiple comparison test or the Kruskal-Wallis test with Dunn’s multiple comparison test (*P < .05, **P < .01, ***P < .001, ****P < .0001).
ns, not significant.